We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-15.5%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$336M
AUM Growth
-$19.6M
(-5.5%)
Cap. Flow
+$49.3M
Cap. Flow
% of AUM
14.69%
Top 10 Holdings %
Top 10 Hldgs %
64.26%
Holding
65
New
14
Increased
15
Reduced
7
Closed
11
Avg Time Held Equity + Options
2.8
quarters
Top 10 Avg Time Held Equity + Options
1.8
quarters
Top 20 Avg Time Held Equity + Options
1.5
quarters
Avg Time Held Equity only
2.8
quarters
Top 10 Avg Time Held Equity only
1.8
quarters
Top 20 Avg Time Held Equity only
1.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$25.3M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$23.8M |
| 3 |
Globus Medical
GMED
|
+$17.1M |
| 4 |
Embecta
EMBC
|
+$10.9M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$9.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$27.1M |
| 2 |
Sanofi
SNY
|
+$18.7M |
| 3 |
Viatris
VTRS
|
+$9.09M |
| 4 |
Organon & Co
OGN
|
+$9.05M |
| 5 |
Labcorp
LH
|
+$7.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.81% |
| 2 | Industrials | 9.51% |
| 3 | Miscellaneous | 1.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Icon
ICLR
$13B
| $35.6M | 10.59% |
203,311
+7,811
| +4% | +$1.51M |
2024 Q4
1 quarter
|
|
2
Maximus
MMS
$3.01B
| $31.9M | 9.51% |
468,352
+86,929
| +23% | +$6.19M |
2024 Q3
2 quarters
|
|
|
3
Merck
MRK
$360B
| $24.3M | 7.23% |
+270,596
| New | +$25.3M |
2025 Q1
0 quarters
|
|
4
Zimmer Biomet
ZBH
$17.3B
| $21.2M | 6.33% |
187,685
+12,874
| +7% | +$1.38M |
2023 Q3
6 quarters
|
|
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $20.7M | 6.18% |
+187,573
| New | +$23.8M |
2025 Q1
0 quarters
|
|
|
6
Labcorp
LH
$25.8B
| $19.5M | 5.81% |
83,873
-29,420
| -26% | -$7.14M |
2023 Q2
7 quarters
|
|
7
Bright Minds Biosciences
DRUG
$517M
| $18.3M | 5.45% |
507,562
+55,769
| +12% | +$2.04M |
2024 Q4
1 quarter
|
|
|
8
Globus Medical
GMED
$10.2B
| $15.2M | 4.51% |
+207,000
| New | +$17.1M |
2025 Q1
0 quarters
|
|
9
Teleflex
TFX
$5.26B
| $14.9M | 4.44% |
107,780
+41,008
| +61% | +$6.64M |
2023 Q3
6 quarters
|
|
|
10
Embecta
EMBC
$350M
| $14.1M | 4.21% |
1,107,613
+682,039
| +160% | +$10.9M |
2024 Q4
1 quarter
|
|
|
11
BioMarin Pharmaceuticals
BMRN
$10.7B
| $9.98M | 2.97% |
+141,134
| New | +$9.49M |
2025 Q1
0 quarters
|
|
12
Anteris Technologies
AVR
$616M
| $8.63M | 2.57% |
2,369,960
-40
| -0% | -$257 |
2024 Q4
1 quarter
|
|
13
Haemonetics
HAE
$5.51B
| $8.51M | 2.54% |
+133,966
| New | +$9.11M |
2025 Q1
0 quarters
|
|
14
Annexon
ANNX
$707M
| $6.56M | 1.95% |
3,397,786
+1,030,779
| +44% | +$3.43M |
2024 Q3
2 quarters
|
|
15
Protara Therapeutics
TARA
$151M
| $6.45M | 1.92% |
1,514,300
+76,800
| +5% | +$343K |
2024 Q4
1 quarter
|
|
16
ANI Pharmaceuticals
ANIP
$1.63B
| $5.84M | 1.74% |
87,298
-72,753
| -45% | -$4.35M |
2024 Q4
1 quarter
|
|
17
PUT
DELISTED
Soleno Therapeutics
SLNO
| $5.59M | 1.67% |
+78,300
| New | +$3.81M |
2025 Q1
0 quarters
|
|
18
Septerna Inc
SEPN
$1.69B
| $4.57M | 1.36% |
788,670
+516,983
| +190% | +$5.9M |
2024 Q4
1 quarter
|
|
19
Praxis Precision Medicines
PRAX
$6.72B
| $4.26M | 1.27% |
+112,500
| New | +$7.03M |
2025 Q1
0 quarters
|
|
20
DELISTED
Avanos Medical
AVNS
| $4.1M | 1.22% |
+285,989
| New | +$4.47M |
2025 Q1
0 quarters
|
|
21
PMV Pharmaceuticals
PMVP
$71.6M
| $4.07M | 1.21% |
3,735,396
+163,229
| +5% | +$222K |
2024 Q2
3 quarters
|
|
22
Tyra Biosciences
TYRA
$1.27B
| $3.87M | 1.15% |
416,617
+175,747
| +73% | +$2.27M |
2024 Q1
4 quarters
|
|
23
Disc Medicine
IRON
$2.17B
| $3.65M | 1.09% |
73,511
| – | – |
2024 Q2
3 quarters
|
|
24
DELISTED
89bio
ETNB
| $3.63M | 1.08% |
+500,000
| New | +$4.37M |
2025 Q1
0 quarters
|
|
25
DELISTED
Akero Therapeutics
AKRO
| $3.44M | 1.02% |
+85,000
| New | +$3.6M |
2025 Q1
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Sio Capital Management held 65 positions worth $336M, down 5.5% from $355M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Sio Capital Management deployed $49.3M of net new capital in Q1 2025, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Merck: 270,596 shares worth $24.3M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier, followed by Industrials and Miscellaneous.
On the sell side, the largest reduction was Labcorp, an estimated $7.14M trimmed.
- Sio Capital Management's largest Q1 2025 buy was Merck: 270,596 shares worth $24.3M.
- Sio Capital Management added most to Embecta in Q1 2025, an estimated $10.9M increase.
- Sio Capital Management's biggest Q1 2025 reduction was Labcorp, cutting an estimated $7.14M.
- Sio Capital Management fully exited Cigna in Q1 2025, selling an estimated $27.1M.
- Sio Capital Management's ten largest holdings make up 64% of its $336M portfolio in Q1 2025.
- Sio Capital Management opened 14 new positions and closed 11 in Q1 2025.
- Sio Capital Management's portfolio value fell 5.5% quarter-over-quarter to $336M.
Based on Sio Capital Management's 13F filing for Q1 2025, filed 15 May 2025.